Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders

Irish Journal of Medical Science

Volumn 176, Issue 2, 2007, Pages 105-109

  Langabeer, S E ^a   Ni Ainle, F ^a   Conneally, E ^a   Lawler, M ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Essential thrombocythaemia; Idiopathic myelofibrosis; JAK2 V617F; Myeloproliferative disorders; Polycythaemia vera; Tyrosine kinase

Indexed keywords

DNA; JANUS KINASE 2; PHENYLALANINE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DNA EXTRACTION; DRUG TARGETING; GENE MUTATION; GENETIC SCREENING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

CHRONIC DISEASE; HUMANS; JANUS KINASE 2; MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 34250763759     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-007-0026-x     Document Type: Article

References (35)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World health organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
2. Hughes T, Branford S (2006) Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20:29-41
3. Deininger M, Buchdunger E, Druker BJ (2005) The development of Imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 105:2640-2653
4. Frohling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 23:6285-6295
5. Kralovics R, Skoda RC (2005) Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders. Blood Rev 19:1-13
6. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
7. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Eng J Med 352:1779-1790
8. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
9. James C, Ugo V, Le Couedic JP, et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148
10. Jones AV, Kreil S, Zoi K et al (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106:2162-2168
11. Zhao R, Xing S, Li Z, Li Q, Krantz SB, Zhao ZJ (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792
12. Yamaoka K, Saharinen P, Pesu M, Holt VET, Silvennoinen O, O'Shea JJ (2004) The janus kinases (Jaks). Genome Biol 5:253
13. Kaushansky K (2005) On the molecular origins of the chronic myeloproliferative disorders: It all makes sense. Blood 105:4187-4190
14. Jelinek J, Oki Y, Gharibyan V et al (2005) JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML and megakaryoblastic leukaemia. Blood 106:3370-3373
15. Levine RL, Loriaux M, Huntly BJ et al (2005) The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukaemia and acute myeloid leukaemia, but not in acute lymphoblastic leukaemia or chronic lymphocytic leukaemia. Blood 106:3377-3379
16. Lee JW, Kim YG, Soung YH et al (2006) The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25:1434-1436
17. Ohyashiki K, Aota Y, Akahane D et al (2005) The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 19:2359-2360
18. Tono C, Xu G, Toki T et al (2005) JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukaemia. Leukemia 19:1843-1844
19. McLornan DP, Percy MJ, Jones AV, Cross NC, McMullin MF (2005) Chronic neutrophilic leukaemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 90:1696-1697
20. Melzner I, Weniger MA, Menz CK, Moller P (2006) Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia 20:157-158
21. Lee JW, Soung YH, Kim SY et al (2006) JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas. Leuk Lymphoma 47:313-314
22. Sulong S, Case M, Minto L, Wilkins B, Hall A, Irving J (2005) The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukaemia. Brit J Haematol 130:964-965
23. van Dongen JJ, Macintyre EA, Gabert JA et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: Investigation of minimal residual disease in acute leukaemia. Leukemia 13:1901-1928
24. Campbell PJ, Green AR (2005) Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program), pp 201-208
25. Johan MF, Goodeve AC, Bowen DT, Frew MF, Reilly JT (2005) JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia. Brit J Haematol 130:968
26. Steensma DP, Dewald GW, Lasho TL et al (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes. Blood 106:1207-1209
27. Scott LM, Campbell PJ, Baxter EJ et al (2005) The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106:2920-2921
28. Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous and homozygous JAK2 (V617F) in polycythemia vera. Cancer 106:631-635
29. Wolanskyj AP, Lasho TL, Schwager SM et al (2005) JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Brit J Haematol 131:208-213
30. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Brit J Haematol 132:244-245
31. Tefferi A, Lasho TL, Schwager SM et al (2005) The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: Lineage specificity and clinical correlates. Brit J Haematol 131:320-328
32. Campbell PJ, Griesshammer M, Dohner K et al (2006) The V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107:2098-2100
33. Bench A, Li J, Huntly BJ et al (2004) Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. Brit J Haematol 127:509-518
34. Futterer A, Campanero MR, Leonardo E et al (2005) Dido gene expression alterations are implicated in the induction of haematological myeloid neoplasms. J Clin Invest 115:2351-2362
35. Chalandon Y, Schwaller J (2005) Targeting mutated protein tyrosine kinases and their signalling pathways in hematologic malignancies. Haematologica 90:949-968